AB
Andrew Berens Leerink Partners Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Celcuity
CELC
$2.31B
| $54.47 | $60 |
10%
upside
| Outperform | 1 month ago |
|
2
Cogent Biosciences
COGT
$1.81B
| $12.94 | $18 |
39%
upside
| Outperform | 1 month ago |
|
3
Nuvalent
NUVL
$5.74B
| $79.67 | $140 |
76%
upside
| Outperform | 2 months ago |
|
4
Arvinas
ARVN
$559M
| $7.61 | $9 |
18%
upside
| Market Perform | 3 months ago |
|
5
Compass Therapeutics
CMPX
$466M
| $3.37 | $6 |
78%
upside
| Outperform | 5 months ago |
|
6
Regeneron Pharmaceuticals
REGN
$60.1B
| $567.22 | $762 |
34%
upside
| Market Perform | 7 months ago |
|
7
Zymeworks
ZYME
$1.07B
| $14.08 | $25 |
78%
upside
| Outperform | 10 months ago |
|
8
Gilead Sciences
GILD
$140B
| $112.77 | $96 |
15%
downside
| Outperform | 10 months ago |
|
9
Agios Pharmaceuticals
AGIO
$2.1B
| $36.13 | $56 |
55%
upside
| Market Perform | 11 months ago |
|
10
Incyte
INCY
$16.7B
| $85.44 | $78 |
9%
downside
| Outperform | 1 year ago |
|
11
Merus
MRUS
$5.01B
| $66.23 | $48 |
28%
downside
| Outperform | 2 years ago |
|
|
12
Incyte
INCY
$16.7B
| $85.44 | $60 |
30%
downside
| Underperform | 2 years ago |
|
|
13
Zymeworks
ZYME
$1.07B
| $14.08 | $10 |
29%
downside
| Market Perform | 2 years ago |
|
|
14
Cogent Biosciences
COGT
$1.81B
| $12.94 | $20 |
55%
upside
| Outperform | 2 years ago |
|
15
Nurix Therapeutics
NRIX
$697M
| $9.12 | $28 |
207%
upside
| Outperform | 2 years ago |
|
|
16
Arvinas
ARVN
$559M
| $7.61 | $70 |
820%
upside
| Outperform | 2 years ago |
|
17
AstraZeneca
AZN
$254B
| $81.78 | $79 |
3%
downside
| Outperform | 2 years ago |
|
|
18
Merus
MRUS
$5.01B
| $66.23 | $35 |
47%
downside
| Outperform | 2 years ago |
|
|
19
Agios Pharmaceuticals
AGIO
$2.1B
| $36.13 | $37 |
2%
upside
| Outperform | 3 years ago |
|
20
Cullinan Oncology
CGEM
$408M
| $6.91 | $25 |
262%
upside
| Outperform | 3 years ago |
|
|
21
Compass Therapeutics
CMPX
$466M
| $3.37 | $11 |
226%
upside
| Outperform | 3 years ago |
|
22
Aura Biosciences
AURA
$399M
| $6.42 | $40 |
523%
upside
| Outperform | 3 years ago |
|
23
Monte Rosa Therapeutics
GLUE
$303M
| $4.91 | $20 |
307%
upside
| Market Perform | 3 years ago |
|
24
Tango Therapeutics
TNGX
$760M
| $6.83 | $25 |
266%
upside
| Outperform | 4 years ago |
|